Isolation of Small Extracellular Vesicles from Murine Skeletal Muscle and Bone Marrow by Size-Exclusion Chromatography
June 23rd, 2026
This protocol describes the isolation of small extracellular vesicles from murine skeletal muscle and bone marrow using enzymatic digestion and size-exclusion chromatography, enabling reproducible recovery of vesicle-enriched fractions from structurally complex, low-yield tissues for downstream molecular analysis.
Our research focuses on isolating small extracellular vesicles from mouse muscle and bone marrow to understand how tissues exchange signals. This protocol can be applied to studies pertaining to aging, muscle regeneration, exercise physiology, and bone marrow pathophysiological studies in mouse models. To begin, place the murine femur and tibia samples in a biosafety cabinet.
Pre-weigh and label 1.5 milliliter centrifuge tubes. Next, puncture the bottom of a 0.2 milliliter tube with a sterile 16-gauge needle held perpendicular to the base, producing a single uniform opening. Insert the punctured tube into the pre-weighed 1.5 milliliter centrifuge tube with a snug fit to prepare the poked tube setup.
Place the leg bones in a sterile Petri dish. Separate the femur and tibia by cutting through the joint space. Cut both ends of the femur and tibia to expose the red marrow.
Place the bones into the punctured PCR tube, which is positioned inside the 1.5 milliliter tube, and seal the assembly with parafilm. Centrifuge the sample for 10 seconds in a benchtop microcentrifuge at approximately 8, 000 g at room temperature. Verify successful marrow extraction by the presence of visibly white bones, devoid of residual red marrow in the upper tube, and the dark red and compact pellet at the bottom of the lower tube.
Then weigh the 1.5 milliliter tube again to determine the mass of the extracted marrow to ensure it falls within the expected range of approximately 15 to 30 milligrams per mouse. Add 250 microliters of RPMI 1640 to each tube containing the bone marrow and place the samples on ice. Resuspend the marrow by gently pipetting up and down 10 to 15 times using a P1000 pipette until a homogeneous suspension is obtained with no remaining clumps or intact tissue fragments.
Centrifuge the sample at 300 g for 10 minutes at four degrees Celsius to pellet undigested debris, intact cells, and remaining tissue fragments. Carefully transfer the supernatant to a new sterile 1.5 milliliter microcentrifuge tube without disturbing the pellet. Centrifuge the transferred supernatant at 2, 000 g for 15 minutes to remove large debris.
Collect the supernatant into a new tube and centrifuge again at 10, 000 g for 30 minutes at four degrees Celsius. Then collect at least 200 microliters of the final supernatant in a fresh tube. Equilibrate the size exclusion chromatography column by flushing it with six milliliters of filtered PBS, maintaining the column and the PBS at room temperature.
Allow the entire volume to pass through the column by gravity. Then load 150 microliters of the filtered supernatant onto the column and allow the sample to enter the resin completely. The endpoint is reached when the liquid meniscus reaches the surface of the resin bed with no visible liquid remaining above the wet resin.
Immediately add 550 microliters of PBS to initiate elution and collect the void volume of 700 microliters. Discard the void volume or retain it as a non-extracellular vesicle fraction. Begin collecting the extracellular vesicle enriched fraction immediately after the 700 microliter void volume has eluded.
Ensure that 850 microliters of extracellular vesicle enriched elute is collected. To concentrate the extracellular vesicle, load the sample into a pre-rinsed centrifugal filter with a 100 kilodalton molecular weight cutoff. Centrifuge the sample at 4, 000 g at four degrees Celsius, checking every two to three minutes until the desired final volume is reached.
Then recover the retentate by gentle pipetting. Keep the extracellular vesicle enriched fractions on ice for immediate assays, such as transmission electron microscopy. Western blot analysis showed the presence of small extracellular vesicles, or SEV markers in early fractions.
Fractions one to five were pooled for the subsequent characterization of small extracellular vesicles. The absence of calnexin and binding immunoglobulin protein signals in these fractions ruled out contamination from intracellular membranes and endoplasmic reticulum components. Transmission electron microscopy of SEV enriched fractions F1 to F5 revealed intact round vesicles with clearly defined membrane bilayers and diameters below 200 nanometers.
Nanoparticle tracking analysis of the pooled sample demonstrated a unimodal size distribution centered below 200 nanometers with a median particle diameter of 147.8 nanometers. Particle concentration normalized to tissue mass was highest in SEV enriched fractions F1 to F5 at 3.7 times 10 to the power of eight particles per milliliters per milligram tissue and slightly reduced in later fractions F6 to F8 at 3.7 times 10 to the power of eight particles per milliliter per milligram tissue. This protocol allows researchers to measure size, concentration, and molecular cargo of extracellular vesicles from muscle and bone marrow.
Future research can extend this protocol to disease models and use the isolated vesicles to identify biomarkers and therapeutic targets.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol details a reproducible workflow for isolating small extracellular vesicles (sEVs) from mouse skeletal muscle (SkM) and bone marrow (BM) tissues. SkM undergoes enzymatic digestion, while BM is processed directly, followed by differential centrifugation and size-exclusion chromatography (SEC) to obtain EV-enriched fractions. The method enables high-purity sEV isolation from minimal tissue input, supporting downstream molecular and functional analyses.
Key Study Components
Area of Science
- Extracellular vesicle biology
- Tissue-specific vesicle isolation
- Nanoparticle characterization
Background
- sEVs mediate intercellular communication via transfer of proteins, lipids, and RNAs.
- Isolating sEVs from solid tissues like SkM and BM is challenging due to low yield and contamination.
- Existing methods often require large tissue inputs and lack reproducibility.
- SEC is effective for separating EVs from contaminants based on size.
- Validation of EV purity requires multiple orthogonal techniques.
Purpose of Study
- Develop a reliable method for sEV isolation from mouse SkM and BM.
- Minimize tissue input requirements while maximizing yield and purity.
- Provide a standardized protocol using differential centrifugation and SEC.
- Enable downstream molecular and functional analysis of tissue-derived sEVs.
- Support research in intercellular communication in musculoskeletal and hematopoietic systems.
Methods Used
- Enzymatic digestion of skeletal muscle tissue.
- Direct processing of bone marrow without enzymatic treatment.
- Differential centrifugation to remove cells and debris.
- Size-exclusion chromatography (SEC) for EV enrichment.
- Discard of void volumes (SkM: ~2.5 mL; BM: 700 µL) followed by collection of EV-enriched fractions.
- Subfractionation into sequential aliquots (SkM: F1–F4; BM: F1–F5).
- Transmission electron microscopy (TEM) for morphology assessment.
- Nanoparticle tracking analysis (NTA) for size and concentration.
- Western blotting for canonical EV markers (e.g., tetraspanins).
- Single-particle interferometric detection (SPID) for tetraspanin-defined subpopulation quantification.
Main Results
- sEVs isolated from ~500 µL quadriceps and ~150 µL pooled femur/tibia BM.
- Yield of ~10⁸ particles·mL⁻¹·mg⁻¹ tissue.
- Particle diameters predominantly <200 nm.
- EV-enriched fractions validated by TEM, NTA, and Western blotting.
- SPID enabled quantification of tetraspanin-positive sEV subpopulations.
- Method yields high-purity sEVs suitable for downstream omics and functional assays.
Conclusions
- The protocol enables reproducible, high-purity sEV isolation from structurally complex tissues.
- Minimal input tissue volumes are sufficient for robust EV yield.
- Combined use of differential centrifugation and SEC reduces contamination.
- Orthogonal validation confirms vesicle integrity and purity.
- This approach supports advanced studies of tissue-specific sEV functions in health and disease.
Frequently Asked Questions
Executive Industry Relevance
Isolating small extracellular vesicles (sEVs) from solid tissues like skeletal muscle and bone marrow remains a bottleneck in biomarker discovery and mechanistic studies due to low yield and contamination. This protocol enables reproducible, high-purity sEV isolation from minimal tissue input, supporting target validation and phenotypic screening in musculoskeletal and hematopoietic disease models. By reducing biological noise and improving vesicle purity, the method enhances predictive confidence in downstream omics and functional assays.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of tissue-specific intercellular communication pathways via sEV-mediated transfer of proteins, lipids, and RNAs.
- Operational Value: Provides a reproducible workflow for isolating sEVs from murine skeletal muscle and bone marrow using differential centrifugation and size-exclusion chromatography.
- Scientific Value: Supports biological de-risking by validating EV enrichment through orthogonal methods including TEM, NTA, Western blotting, and single-particle interferometric detection.
Screening & Assay Development
- Scientific Value: Produces EV-enriched fractions with particle diameters predominantly <200 nm and yields of ~10⁸ particles·mL⁻¹·mg⁻¹ tissue, enabling consistent input for screening campaigns.
- Operational Value: Standardizes sEV isolation through defined void volume disposal and sequential fractionation (SkM: F1–F4; BM: F1–F5), improving assay reproducibility across laboratories.
- Scientific Value: Facilitates preparation of validated biological systems for downstream molecular analyses such as proteomics and RNA profiling of tissue-derived vesicles.
Translational & Preclinical Research
- Scientific Value: Supports disease-relevant systems by enabling isolation of sEVs from skeletal muscle and bone marrow, tissues central to musculoskeletal and hematopoietic pathophysiology.
- Operational Value: Uses minimal input material (~500 µL quadriceps, ~150 µL pooled femur/tibia bone marrow), allowing scalable processing of limited preclinical samples.
- Scientific Value: Enhances translational biomarker alignment by isolating tetraspanin-defined sEV subpopulations quantifiable via single-particle interferometric detection.
Pipeline & Workflow Integration
The method fits within the discovery continuum from early target validation through preclinical mechanistic studies, enabling reliable isolation of tissue-derived sEVs for hypothesis testing and pathway clarification.
- Discovery Biology: Supports hypothesis testing by isolating sEVs that mediate intercellular communication in skeletal muscle and bone marrow microenvironments.
- Screening: Delivers assay-ready, size-excluded EV fractions with reduced contamination, improving reliability of compound or stimulus response evaluations.
- Analytics: Generates quantitative outputs including particle concentration, size distribution (<200 nm), and tetraspanin subpopulation data to enable comparative analysis across conditions.
- Translational Research: Connects discovery to preclinical continuity by providing purified sEVs suitable for functional uptake and signaling assays in disease models.
- Enterprise Reuse: Establishes a standardized, reusable isolation platform applicable across musculoskeletal and hematopoietic research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence by reducing mechanistic ambiguity through high-purity sEV isolation validated by multiple orthogonal techniques.
- Operational Value: Enhances standardization and reproducibility via defined SEC fractionation and void volume disposal protocols.
- Strategic Value: Improves go/no-go decisions by enabling reliable assessment of tissue-specific vesicle cargo in early discovery.
- Portfolio Impact: Supports risk-adjusted prioritization by providing consistent sEV inputs for biomarker and target validation studies.
Implementation Considerations
- Requires expertise in tissue handling, enzymatic digestion (for skeletal muscle), and centrifugation techniques.
- Dependent on access to size-exclusion chromatography columns, nanoparticle tracking analysis, and Western blotting infrastructure.
- Necessitates cross-team standardization of fraction collection and pooling criteria based on EV marker enrichment.
- Involves adaptation considerations when applying to other solid tissues due to differences in extracellular matrix density and cellularity.
- Practical limitation: Low absolute yield from small tissue inputs necessitates sensitive downstream detection methods for omics applications.
